216 related articles for article (PubMed ID: 22294539)
1. Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
Akkus NI; Rajpal S; Agnani S
J Invasive Cardiol; 2012 Feb; 24(2):76-8. PubMed ID: 22294539
[TBL] [Abstract][Full Text] [Related]
2. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Brodie BR
Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
5. Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.
Dirksen MT; Ronner E; Laarman GJ; van Heerebeek L; Slagboom T; van der Wieken LR; van der Wouw PA; Kiemeneij F
J Invasive Cardiol; 2005 Oct; 17(10):512-7. PubMed ID: 16204742
[TBL] [Abstract][Full Text] [Related]
6. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
[TBL] [Abstract][Full Text] [Related]
7. Safety of intra-aortic balloon pump using glycoprotein IIb/IIIa antagonists.
Laish-Farkash A; Hod H; Matetzky S; Guetta V
Clin Cardiol; 2009 Feb; 32(2):99-103. PubMed ID: 19215010
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
Dörler J; Edlinger M; Alber HF; Altenberger J; Benzer W; Grimm G; Huber K; Pachinger O; Schuchlenz H; Siostrzonek P; Zenker G; Weidinger F;
Eur Heart J; 2011 Dec; 32(23):2954-61. PubMed ID: 21920970
[TBL] [Abstract][Full Text] [Related]
9. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
11. The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
Wang TY; Magid DJ; Ting HH; Li S; Alexander KP; Roe MT; Peterson ED
Am Heart J; 2014 Jun; 167(6):833-9. PubMed ID: 24890532
[TBL] [Abstract][Full Text] [Related]
12. Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.
Tcheng JE
J Interv Cardiol; 2006 Oct; 19(5):456-63. PubMed ID: 17020571
[TBL] [Abstract][Full Text] [Related]
13. Emergency percutaneous coronary intervention (PCI) for the care of patients with ST-elevation myocardial infarction (STEMI).
Morrison DA; Berman M; El-Amin O; McLaughlin RT; Bates ER
Minerva Cardioangiol; 2007 Oct; 55(5):593-623. PubMed ID: 17912165
[TBL] [Abstract][Full Text] [Related]
14. Late bare-metal stent thrombosis in a patient with Crohn's disease.
Yazıcı HU; Birdane A; Nadiradze A; Ünalır A
Anadolu Kardiyol Derg; 2011 Aug; 11(5):462-4. PubMed ID: 21733786
[No Abstract] [Full Text] [Related]
15. Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events.
Rinaldi MJ; Kirtane AJ; Piana RN; Caputo RP; Gordon PC; Lopez JJ; Dauerman HL; Ryan TJ; Kiernan FJ; Cutlip DE; Ho KK; Gibson CM; Murphy SA; Cohen DJ
Am Heart J; 2008 Apr; 155(4):654-60. PubMed ID: 18371472
[TBL] [Abstract][Full Text] [Related]
16. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.
Exaire JE; Tcheng JE; Kereiakes DJ; Kleiman NS; Applegate RJ; Moliterno DJ;
Catheter Cardiovasc Interv; 2005 Mar; 64(3):369-72. PubMed ID: 15736260
[TBL] [Abstract][Full Text] [Related]
17. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
18. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
19. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Buller CE; Pate GE; Armstrong PW; O'Neill BJ; Webb JG; Gallo R; Welsh RC
Can J Cardiol; 2006 May; 22(6):511-5. PubMed ID: 16685318
[TBL] [Abstract][Full Text] [Related]
20. Evolving management of ST-segment elevation myocardial infarction: update on recent data.
Cannon CP
Am J Cardiol; 2006 Dec; 98(12A):10Q-21Q. PubMed ID: 17169625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
